National Cancer Data Base report on osteosarcoma of the head and neck

✍ Scribed by Russell B. Smith; Louis W. Apostolakis; Lucy H. Karnell; Brenton B. Koch; Robert A. Robinson; Weining Zhen; Herman R. Menck; Henry T. Hoffman

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 105 KB
• Volume: 98
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.11716

✦ Synopsis

Abstract

BACKGROUND

Osteosarcoma is the most common primary bone malignancy overall but is encountered infrequently in the head and neck. Limited data are available on the significance of prognostics factors and results of therapy for patients with head and neck osteosarcoma (HNOS). It is known that surgical therapy is critical to successful outcome. The impact of adjuvant chemotherapy has not been defined well.

METHODS

The National Cancer Data Base has collected data on cases of HNOS by voluntary accrual from participating hospitals. This database was used to assess patient demographics, tumor characteristics, treatment, and outcome for an 11‐year period extending from 1985 to 1996.

RESULTS

The data set contained 496 cases of HNOS. Overall, the 5‐year disease‐specific survival rate was 59.7%. Factors associated with a poor prognosis were age older than 60 years; nonmandibular tumor location; tumor size > 6 cm; histologic type of osteoblastic, not otherwise specified (NOS); advanced disease stage; nonsurgical initial therapy; and positive margins of resection. Increased use of multimodality therapy was noted during the later years of the study. No substantial difference in the 5‐year survival rate was noted between treatment with surgery alone (74.7%) and surgery with adjuvant chemotherapy (71.3%), despite the greater prevalence of tumors with poor prognostic factors in the surgery and adjuvant chemotherapy group.

CONCLUSIONS

Surgery with clear margins is an important factor in successful therapy for patients with HNOS. Improved survival has been noted within the last 2 decades compared with historic controls. Multiple negative prognostic factors have been identified and should be considered in treatment planning. The role of chemotherapy has not been defined well, but its incorporation into treatment of patients with high‐risk tumors may improve survival. Cancer 2003. © 2003 American Cancer Society.

DOI 10.1002/cncr.11716